Mint Tower Capital Management B.V. Bristol Myers Squibb CO Call Options Transaction History

Mint Tower Capital Management B.V.

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 05, 2022	SELL	$72.62 - $79.98 $4.21 Million - $4.64 Million	-58,000 Closed	0 $0
Q1 2022 Apr 29, 2022	BUY	$61.48 - $73.72 $3.57 Million - $4.28 Million	58,000 New	58,000 $4.24 Million
Q4 2021 Feb 04, 2022	SELL	$53.63 - $62.52 $2.11 Million - $2.46 Million	-39,400 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$59.17 - $69.31 $650,870 - $762,410	-11,000 Reduced 21.83%	39,400 $2.33 Million
Q2 2021 Aug 02, 2021	BUY	$61.91 - $67.42 $1.13 Million - $1.23 Million	18,200 Added 56.52%	50,400 $3.37 Million
Q1 2021 May 12, 2021	BUY	$59.34 - $66.74 $456,918 - $513,897	7,700 Added 31.43%	32,200 $2.03 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $721,750 - $817,875	12,500 Added 104.17%	24,500 $15,000
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $513,240 - $608,520	12,000 New	12,000 $609,000
Q3 2018 Nov 06, 2018	SELL	$55.19 - $62.25 $689,875 - $778,125	-12,500 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$50.53 - $62.98 $631,625 - $787,250	12,500 New	12,500 $692,000

2,402

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $112B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Mint Tower Capital Management B.V., based on Form 13F filings with the SEC.

Stay updated on Mint Tower Capital Management B.V. with notifications on news.